Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
Venous thromboembolism (VTE) is a disease that includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), is an important cause of morbidity and mortality worldwide. VTE is the third most common cardiovascular illness after acute coronary syndrome and stroke. Unfractionated heparin, low-m...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Kazimierz Wielki University
2017-08-01
|
Series: | Journal of Education, Health and Sport |
Subjects: | |
Online Access: | http://www.ojs.ukw.edu.pl/index.php/johs/article/view/4833 |
id |
doaj-b45d47af9cff424aaf2bc2412c2b0bd4 |
---|---|
record_format |
Article |
spelling |
doaj-b45d47af9cff424aaf2bc2412c2b0bd42020-11-25T00:12:42ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062017-08-017883684610.5281/zenodo.8933514555Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?Łukasz Wołowiec0Daniel Rogowicz1Krystian Kałużny2Anna Kałużna3Walery Zukow4II Katedra Kardiologii, Wydział Nauk o Zdrowiu, Uniwersytet Mikołaja Kopernika w ToruniuII Katedra Kardiologii, Wydział Nauk o Zdrowiu, Uniwersytet Mikołaja Kopernika w ToruniuKatedra i Klinika Rehabilitacji, Wydział Nauk o Zdrowiu, Uniwersytet Mikołaja Kopernika w ToruniuKatedra i Klinika Rehabilitacji, Wydział Nauk o Zdrowiu, Uniwersytet Mikołaja Kopernika w ToruniuKatedra Gospodarki Przestrzennej i Turyzmu, Wydział Nauk o Ziemi, Uniwersytet Mikołaja Kopernika w ToruniuVenous thromboembolism (VTE) is a disease that includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), is an important cause of morbidity and mortality worldwide. VTE is the third most common cardiovascular illness after acute coronary syndrome and stroke. Unfractionated heparin, low-molecular-weight heparin, and warfarin have been the foundation of venous thromboembolism (VTE) prevention and treatment but are being replaced step-by-step by recently approved non-vitamin K antagonist oral anticoagulants (NOACs). Betrixaban is a direct FXa inhibitor with clear pharmacological characteristics: minimal renal clearance, minimal hepatic metabolism, and long half-life. FDA and Portola Pharmaceuticals on June 23 announced the approval of betrixaban to reduce the risk of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who have restricted mobility or other risk factors for thromboembolic complications. FDA stated that it approved the drug on the basis of data from the Acute Medically Ill VTE Prevention With Extended Duration Betrixaban (APEX) trial. The APEX trial compared thromboembolic event and death rates in acutely ill patients treated with betrixaban capsules for 35–42 days or subcutaneously administered enoxaparin for 6–14 days. All study participants had been hospitalized for heart failure, respiratory failure, infection without septic shock, rheumatic disorders, or ischemic stroke. Among hospitalized medically ill patients, extended-duration betrixaban demonstrates a favorable net clinical outcome and is associated with an ≈ 30% reduction in fatal or irreversible ischemic or bleeding events compared with standard-duration enoxaparin followed by placebo.http://www.ojs.ukw.edu.pl/index.php/johs/article/view/4833non-vitamin k oral anticoagulants, new oral anticoagulants, betrixaban, venous thromboembolism |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Łukasz Wołowiec Daniel Rogowicz Krystian Kałużny Anna Kałużna Walery Zukow |
spellingShingle |
Łukasz Wołowiec Daniel Rogowicz Krystian Kałużny Anna Kałużna Walery Zukow Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different? Journal of Education, Health and Sport non-vitamin k oral anticoagulants, new oral anticoagulants, betrixaban, venous thromboembolism |
author_facet |
Łukasz Wołowiec Daniel Rogowicz Krystian Kałużny Anna Kałużna Walery Zukow |
author_sort |
Łukasz Wołowiec |
title |
Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different? |
title_short |
Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different? |
title_full |
Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different? |
title_fullStr |
Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different? |
title_full_unstemmed |
Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different? |
title_sort |
non-vitamin k oral anticoagulant in the prevention and treatment of venous thromboembolism. why betrixaban is different? |
publisher |
Kazimierz Wielki University |
series |
Journal of Education, Health and Sport |
issn |
2391-8306 |
publishDate |
2017-08-01 |
description |
Venous thromboembolism (VTE) is a disease that includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), is an important cause of morbidity and mortality worldwide. VTE is the third most common cardiovascular illness after acute coronary syndrome and stroke.
Unfractionated heparin, low-molecular-weight heparin, and warfarin have been the foundation of venous thromboembolism (VTE) prevention and treatment but are being replaced step-by-step by recently approved non-vitamin K antagonist oral anticoagulants (NOACs).
Betrixaban is a direct FXa inhibitor with clear pharmacological characteristics: minimal renal clearance, minimal hepatic metabolism, and long half-life. FDA and Portola Pharmaceuticals on June 23 announced the approval of betrixaban to reduce the risk of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who have restricted mobility or other risk factors for thromboembolic complications. FDA stated that it approved the drug on the basis of data from the Acute Medically Ill VTE Prevention With
Extended Duration Betrixaban (APEX) trial.
The APEX trial compared thromboembolic event and death rates in acutely ill patients treated with betrixaban capsules for 35–42 days or subcutaneously administered enoxaparin for 6–14 days. All study participants had been hospitalized for heart failure, respiratory failure, infection without septic shock, rheumatic disorders, or ischemic stroke. Among hospitalized medically ill patients, extended-duration betrixaban demonstrates a favorable net clinical outcome and is associated with an ≈ 30% reduction in fatal or irreversible ischemic or bleeding events compared with standard-duration enoxaparin followed by placebo. |
topic |
non-vitamin k oral anticoagulants, new oral anticoagulants, betrixaban, venous thromboembolism |
url |
http://www.ojs.ukw.edu.pl/index.php/johs/article/view/4833 |
work_keys_str_mv |
AT łukaszwołowiec nonvitaminkoralanticoagulantinthepreventionandtreatmentofvenousthromboembolismwhybetrixabanisdifferent AT danielrogowicz nonvitaminkoralanticoagulantinthepreventionandtreatmentofvenousthromboembolismwhybetrixabanisdifferent AT krystiankałuzny nonvitaminkoralanticoagulantinthepreventionandtreatmentofvenousthromboembolismwhybetrixabanisdifferent AT annakałuzna nonvitaminkoralanticoagulantinthepreventionandtreatmentofvenousthromboembolismwhybetrixabanisdifferent AT waleryzukow nonvitaminkoralanticoagulantinthepreventionandtreatmentofvenousthromboembolismwhybetrixabanisdifferent |
_version_ |
1725397960705966080 |